Reablation of atrial fibrillation targeting electrogram dispersion in patients with isolated veins: The RESTART trial.
John D Hummel, Paul C Zei, Mark Metzl...
https://pubmed.ncbi.nlm.nih.gov/41638617/Actively Recruiting
Led by Volta Medical · Updated on 2026-06-22
150
Participants Needed
3
Research Sites
N/A
Total Duration
Researchers are evaluating the safety and performance of the latest Volta Medical AI software called Volta AF-Xplorer II during catheter ablation procedures for atrial fibrillation and related arrhythmias. This observational study, named VOLTAIRE-AF, observes how the AI software performs in real-world clinical practice without changing usual treatment workflows. The study follows patients for up to 24 months to assess both acute and long-term outcomes. Participants undergo catheter ablation where the Volta AF-Xplorer II software is used during the mapping phase to identify patient-specific areas of interest in the heart. The actual ablation method is chosen by the treating doctor based on standard care. After the procedure, participants receive follow-up visits scheduled quarterly within the first 9 months and then annually up to 24 months to monitor their heart condition and treatment effects. During the study, patients are monitored for adverse events, recurrence of arrhythmias, and symptoms related to heart failure and atrial fibrillation using standard scores NYHA and EHRA. Quality of life is assessed before the procedure and at least annually using the EQ-5D-3L questionnaire. The main outcomes include freedom from arrhythmia recurrence, serious incidents related to the AI software or ablation, and progression of symptoms and hospitalizations over the 24-month follow-up period.
CONDITIONS
VOLta Medical AI-software in REal-World During AF Ablation
P
Paola MILPIED
C
Cecile BIELMANN
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Volta Medical
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 screening visit
Duration - Procedure day
Participants undergo catheter ablation for atrial fibrillation using the Volta AF-Xplorer II AI software during the mapping phase. The ablation approach is determined by the treating doctor according to usual practice.
1 procedure visit (in-person)
Duration - 24 months
Participants have follow-up visits scheduled quarterly within the first 9 months and then annually up to 24 months. These visits monitor heart rhythm, symptoms, adverse events, and quality of life.
Quarterly visits at 3, 6, and/or 9 months; annual visits thereafter
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
John D Hummel, Paul C Zei, Mark Metzl...
https://pubmed.ncbi.nlm.nih.gov/41638617/Isabel Deisenhofer, Julien Seitz, Marie-Sophie Nguyen-Tu...
https://pubmed.ncbi.nlm.nih.gov/41311304/Isabel Deisenhofer, Jean-Paul Albenque, Sonia Busch...
https://pubmed.ncbi.nlm.nih.gov/39953289/Isabel Deisenhofer, Julien Seitz, Sabine Lotteau...
https://pubmed.ncbi.nlm.nih.gov/41242590/Volta Medical
Lead Sponsor